25,000 Shares in Artivion, Inc. $AORT Purchased by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. bought a new stake in Artivion, Inc. (NYSE:AORT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 25,000 shares of the company’s stock, valued at approximately $562,000. Tocqueville Asset Management L.P. owned approximately 0.05% of Artivion as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Artivion during the second quarter valued at approximately $149,965,000. Vanguard Group Inc. grew its stake in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after purchasing an additional 141,030 shares in the last quarter. Morgan Stanley increased its position in shares of Artivion by 0.8% during the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock worth $102,930,000 after purchasing an additional 18,248 shares during the last quarter. State Street Corp increased its position in shares of Artivion by 2.9% during the 4th quarter. State Street Corp now owns 1,584,920 shares of the company’s stock worth $72,288,000 after purchasing an additional 44,641 shares during the last quarter. Finally, Fred Alger Management LLC raised its stake in shares of Artivion by 4.2% during the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after purchasing an additional 55,322 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Insider Buying and Selling

In other news, CEO James P. Mackin sold 70,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the sale, the chief executive officer directly owned 877,275 shares in the company, valued at approximately $25,397,111.25. The trade was a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 977 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the sale, the senior vice president directly owned 184,118 shares in the company, valued at $5,245,521.82. The trade was a 0.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 114,978 shares of company stock worth $2,965,155 in the last three months. 6.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on AORT. Citizens Jmp cut their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Needham & Company LLC restated a “buy” rating and set a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a report on Monday, June 1st. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Citigroup reiterated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Artivion Stock Performance

NYSE AORT opened at $28.16 on Friday. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $1.37 billion, a P/E ratio of -402.23 and a beta of 1.25. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25. The firm has a 50-day moving average price of $25.08 and a two-hundred day moving average price of $30.14.

Artivion (NYSE:AORT) last released its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The company had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current year.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.